PARTICULARS TO APPEAR ON THE OUTER PACKAGE
Cardboard box
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
Rheumocam 330 mg, granules for horses. meloxicam
2. STATEMENT OF ACTIVE SUBSTANCES
One sachet contains: 330 mg of meloxicam.
3. PHARMACEUTICAL FORM
Granules in sachet
4. PACKAGE SIZE
100 sachets 10 sachets
5. TARGET SPECIES
Horses.
6. INDICATION(S)
7. METHOD AND ROUTE(S) OF ADMINISTRATION
In-feed use. Read the package leaflet before use.
8. WITHDRAWAL PERIOD(S)

Withdrawal period: Meat and offal: 3 days.

Not authorised for use in lactating animals producing milk for human consumption.

9. SPECIAL WARNING(S), IF NECESSARY

Each sachet contains one dose for a horse weighing 500 kg - 600 kg. The dose must not be divided.

10. EXPIRY DATE

EXP {month/year}

11. SPECIAL STORAGE CONDITIONS

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Disposal: read package leaflet.

13. THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

For animal treatment only. To be supplied only on veterinary prescription.

14. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Chanelle Pharmaceuticals Manufacturing Ltd. Loughrea Co. Galway Ireland

16. MARKETING AUTHORISATION NUMBER

Vm 08749/5023

17. MANUFACTURER'S BATCH NUMBER

BN{number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
Sachet
4 NAME OF THE VETERINARY MEDICINAL PROPRIOT
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
Rheumocam 330 mg, granules for horses. meloxicam
2. QUANTITY OF THE ACTIVE SUBSTANCE(S)
Meloxicam 330 mg
3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES
4. ROUTE(S) OF ADMINISTRATION
In-feed use
5. WITHDRAWAL PERIOD(S)
Withdrawal period: Meat and offal: 3 days. Not authorised for use in lactating animals producing milk for human consumption.
6. BATCH NUMBER
BN {number}
7. EXPIRY DATE
EXP {month/year}
8. THE WORDS "FOR ANIMAL TREATMENT ONLY"
For animal treatment only.

PACKAGE LEAFLET: Rheumocam 330 mg granules for horses

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder and manufacturer responsible for batch release: Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
Ireland

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Rheumocam 330 mg granules for horses. Meloxicam

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

One sachet contains: 330 mg of meloxicam. Pale yellow granules.

4. INDICATION(S)

Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in horses weighing between 500 and 600 kg.

5. CONTRAINDICATIONS

Do not use in pregnant or lactating mares.

Do not use in horses suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

Do not use in horses less than 6 weeks of age.

6. ADVERSE REACTIONS

Isolated cases of adverse reactions typically associated with non-steroidal anti-inflammatory drugs (NSAIDs) were observed in clinical trials (slight urticaria, diarrhoea). Symptoms were reversible. In very rare cases loss of appetite, lethargy, abdominal pain and colitis have been reported.

In very rare cases anaphylactoid reactions, which may be serious (including fatal), may occur and should be treated symptomatically.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reactions)
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

7. TARGET SPECIES

Horses.

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

In-feed use.

To be administered mixed with food at a dose of 0.6 mg/kg body weight, once daily, up to 14 days. The product should be added to 250 g of muesli feed, prior to feeding.

Each sachet contains one dose for a horse weighing between 500 kg and 600 kg and the dose must not be divided into smaller doses.

9. ADVICE ON CORRECT ADMINISTRATION

Avoid introduction of contamination during use.

10. WITHDRAWAL PERIOD(S)

Meat and offal: 3 days.

Not authorised for use in lactating animals producing milk for human consumption.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and the sachet after EXP.

Shelf life after incorporation into muesli feed: use immediately.

12. SPECIAL WARNING(S)

Special precautions for use in animals:

Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity.

In order to minimise risk of intolerance, the product should be mixed into muesli feed.

This product is only for use in horses weighing between 500 and 600 kg.

<u>Special precautions to be taken by the person administering the veterinary medicinal product to animals:</u>

People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product. In case of accidental ingestion, seek medical advice immediately and show this package leaflet or the label to the physician.

Pregnancy and lactation:

Do not use in pregnant or lactating mares.

Interaction with other medicinal products and other forms of interaction:

Do not administer concurrently with glucocorticoids, other NSAIDs or with anticoagulant agents.

Overdose (symptoms, emergency procedures, antidotes):

In the case of overdose symptomatic treatment should be initiated.

Incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIAL, IF ANY

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

15. OTHER INFORMATION

Pack size: 100, 10 sachets.

Not all pack sizes may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

United Kingdom

Chanelle Vet UK Ltd 1 High Street Hungerford Berkshire RG17 0DN – UK

Tel: + 44 1488 680664

Approved 10 November 2021

Menny